Tectonic Therapeutic (NASDAQ:TECX) Shares Gap Up – Here’s Why

Posted by Brenda Bartman on Jul 2nd, 2026

Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $31.99, but opened at $33.48. Tectonic Therapeutic shares last traded at $33.6560, with a volume of 19,365 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a research note on Tuesday, April 21st. Raymond James Financial upgraded shares of Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $76.00 to $81.00 in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a report on Saturday, April 18th. Finally, Stifel Nicolaus started coverage on shares of Tectonic Therapeutic in a research report on Monday, April 13th. They set a “buy” rating and a $75.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $79.40.

Get Our Latest Stock Report on TECX

Tectonic Therapeutic Price Performance

The company has a market cap of $617.80 million, a P/E ratio of -7.34 and a beta of 3.21. The business’s 50 day moving average price is $29.30 and its 200-day moving average price is $26.27.

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.18). As a group, research analysts forecast that Tectonic Therapeutic, Inc. will post -5.46 EPS for the current year.

Insider Buying and Selling

In other Tectonic Therapeutic news, insider Marcella K. Ruddy sold 1,065 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $30.00, for a total value of $31,950.00. Following the transaction, the insider owned 67,682 shares of the company’s stock, valued at approximately $2,030,460. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 39.80% of the company’s stock.

Institutional Trading of Tectonic Therapeutic

A number of hedge funds and other institutional investors have recently made changes to their positions in TECX. Caitong International Asset Management Co. Ltd raised its holdings in shares of Tectonic Therapeutic by 451.6% in the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company’s stock valued at $62,000 after buying an additional 3,247 shares during the last quarter. New York State Common Retirement Fund bought a new stake in Tectonic Therapeutic during the 2nd quarter worth about $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tectonic Therapeutic in the 2nd quarter valued at about $119,000. Los Angeles Capital Management LLC acquired a new stake in Tectonic Therapeutic in the 4th quarter valued at about $134,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Tectonic Therapeutic in the 4th quarter valued at about $135,000. 62.63% of the stock is currently owned by institutional investors and hedge funds.

Tectonic Therapeutic Company Profile

(Get Free Report)

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.